Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 10 December 2014 | By Alexander Gaffney, RAC,
More than a dozen patient groups and trade associations are offering their advice to the US Food and Drug Administration (FDA) on ways the agency can improve its regulatory and administrative processes to take into account the views and expertise of patients and their advocates.
Since 2012, FDA has launched several initiatives meant to better take into account the views of patients. Some, like its patient-focused drug development initiative, have involved patients in more than a dozen meetings and solicited extensive feedback. Others, such as its medical device-focused Patient Preference Initiative (PPI) are still in the early stages of development.
Then, in November 2014, FDA issued an announcement in the Federal Register asking for feedback—and especially feedback from patient groups—about its patient-centric activities, as well as patients' views about the medical product development process.
For more on FDA's announcement, please see our story, "Is FDA Listening Enough to Patients? Agency Wants Feedback."
Now patients and patient advocacy groups alike are responding to FDA's solicitation, offering the agency advice.
Some selected advice follows:
All comments may be found here.
Tags: FDASIA, Patients, Patient Groups, Patient-Centered Drug Development, FDASIA Section 917, Recommendations for FDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.